VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q47708456  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000103.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q47708456‏
024 ‎‡a  0000-0003-0080-7560‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q47708456‏
100 0 ‎‡a  Peter G Smith‏ ‎‡9  es‏ ‎‡9  sl‏ ‎‡9  ast‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  পিটার জি স্মিথ‏ ‎‡c  গবেষক‏ ‎‡9  bn‏
400 0 ‎‡a  Peter G. Smith‏ ‎‡c  researcher (ORCID 0000-0003-0080-7560)‏ ‎‡9  en‏
400 0 ‎‡a  Peter G Smith‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A Case-Control Approach to Examine Diseases for Evidence of Contagion, Including Diseases with Long Latent Periods‏
670 ‎‡a  Author's A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering.‏
670 ‎‡a  Author's A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings‏
670 ‎‡a  Author's A guide for diagnostic evaluations‏
670 ‎‡a  Author's A note on a 'close pairs' test for space clustering‏
670 ‎‡a  Author's A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives‏
670 ‎‡a  Author's A study of burns injuries in Uganda‏
670 ‎‡a  Author's A vaccine against malaria: a substantial step forward‏
670 ‎‡a  Author's Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy‏
670 ‎‡a  Author's Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden‏
670 ‎‡a  Author's Assessment of the RTS,S/AS01 malaria vaccine.‏
670 ‎‡a  Author's Bovine spongiform encephalopathy (BSE) and its epidemiology‏
670 ‎‡a  Author's Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria‏
670 ‎‡a  Author's Cancer Incidence in Five Continents. Comparison between registries: age-standardized rates‏
670 ‎‡a  Author's Case-control approach to examine diseases for evidence of contagion, including diseases with long latent periods.‏
670 ‎‡a  Author's Case-control method for seeking evidence of contagion in Crohn's disease‏
670 ‎‡a  Author's Case-control vaccine effectiveness studies: Data collection, analysis and reporting results‏
670 ‎‡a  Author's Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls‏
670 ‎‡a  Author's Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries‏
670 ‎‡a  Author's Childhood pneumonia and crowding, bed-sharing and nutrition: a case-control study from The Gambia‏
670 ‎‡a  Author's Choices in vaccine trial design in epidemics of emerging infections‏
670 ‎‡a  Author's Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.‏
670 ‎‡a  Author's Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review‏
670 ‎‡a  Author's Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda‏
670 ‎‡a  Author's Congenital malformations; a detailed study of 2500 liveborn infants‏
670 ‎‡a  Author's Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.‏
670 ‎‡a  Author's Contacts between young patients with Hodgkin's disease. A case-control study‏
670 ‎‡a  Author's Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes‏
670 ‎‡a  Author's Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks‏
670 ‎‡a  Author's Current assessment of “case clustering” of lymphomas and leukemias‏
670 ‎‡a  Author's Current epidemiological evidence for transmission of Hodgkin's disease‏
670 ‎‡a  Author's Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine‏
670 ‎‡a  Author's Dermatoglyphics in childhood leukaemia: a guide to prognosis and aetiology?‏
670 ‎‡a  Author's Dermatoglyphics in long-term leukaemic survivors: failure to confirm prognostic value of fingertip pattern‏
670 ‎‡a  Author's Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak‏
670 ‎‡a  Author's Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples‏
670 ‎‡a  Author's Disease Clustering: A Generalization of Knox's Approach to the Detection of Space-Time Interactions‏
670 ‎‡a  Author's Does cotrimoxazole taken by HIV-infected individuals reduce mortality among HIV-uninfected family members? Data may not support conclusion‏
670 ‎‡a  Author's Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting‏
670 ‎‡a  Author's Drug misuse, tobacco smoking, alcohol and other social determinants of tuberculosis in UK-born adults in England: a community-based case-control study‏
670 ‎‡a  Author's Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression‏
670 ‎‡a  Author's Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study‏
670 ‎‡a  Author's Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis‏
670 ‎‡a  Author's Efficacy of leprosy vaccine‏
670 ‎‡a  Author's Embargo on publication of scientific papers by Iranian authors‏
670 ‎‡a  Author's Epidemiological and public health considerations in the design of HIV vaccine trials‏
670 ‎‡a  Author's Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study‏
670 ‎‡a  Author's Epidemiological studies of the 'non-specific effects' of vaccines: I--data collection in observational studies‏
670 ‎‡a  Author's Epidemiology of childhood leukaemia in greater london: A search for evidence of transmission assuming a possibly long latent period‏
670 ‎‡a  Author's Epstein-Barr virus-malaria interaction models for Burkitt's lymphoma: implications for preventive trials‏
670 ‎‡a  Author's Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines‏
670 ‎‡a  Author's Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa‏
670 ‎‡a  Author's Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop‏
670 ‎‡a  Author's Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea‏
670 ‎‡a  Author's Evaluation of diagnostic tests for infectious diseases: general principles‏
670 ‎‡a  Author's Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization‏
670 ‎‡a  Author's Family studies in acute leukaemia in childhood: a possible association with autoimmune disease‏
670 ‎‡a  Author's First generation leishmaniasis vaccines: a review of field efficacy trials‏
670 ‎‡a  Author's Further studies of space-time clustering of Burkitt's lymphoma in Uganda‏
670 ‎‡a  Author's Further studies on chromosome aberration production after whole-body irradiation in man‏
670 ‎‡a  Author's Generalisations of two tests for the detection of household aggregation of disease‏
670 ‎‡a  Author's Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection‏
670 ‎‡a  Author's Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection‏
670 ‎‡a  Author's Human challenge studies to accelerate coronavirus vaccine licensure‏
670 ‎‡a  Author's Human population cytogenetics‏
670 ‎‡a  Author's Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results‏
670 ‎‡a  Author's Influence of birth weight on mortality from infectious diseases: a case-control study‏
670 ‎‡a  Author's Integrating health services for HIV infection, diabetes and hypertension in sub-Saharan Africa: a cohort study‏
670 ‎‡a  Author's Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda‏
670 ‎‡a  Author's Kaposi's Sarcoma in Uganda: Geographic and Ethnic Distribution‏
670 ‎‡a  Author's Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group‏
670 ‎‡a  Author's Leukemia and other cancers following radiation treatment of pelvic disease‏
670 ‎‡a  Author's Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges‏
670 ‎‡a  Author's Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness‏
670 ‎‡a  Author's Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation‏
670 ‎‡a  Author's Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda‏
670 ‎‡a  Author's Making sense of health estimates‏
670 ‎‡a  Author's Malaria vaccine: 3 or 6 months' protection?‏
670 ‎‡a  Author's MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives‏
670 ‎‡a  Author's Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation‏
670 ‎‡a  Author's Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10-11 September 2019‏
670 ‎‡a  Author's Mortality among patients with ankylosing spondylitis not given X-ray therapy‏
670 ‎‡a  Author's Myelosuppressive Effect of Colaspase (L-Asparaginase) in Initial Treatment of Acute Lymphoblastic Leukaemia‏
670 ‎‡a  Author's Non-specific effects of BCG?‏
670 ‎‡a  Author's 'Non-specific effects of vaccines'--an important analytical insight, and call for a workshop.‏
670 ‎‡a  Author's Novel vaccine safety issues and areas that would benefit from further research‏
670 ‎‡a  Author's Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.‏
670 ‎‡a  Author's Person-to-person transmission of hodgkin's disease‏
670 ‎‡a  Author's Placebo use in vaccine trials: recommendations of a WHO expert panel‏
670 ‎‡a  Author's Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania‏
670 ‎‡a  Author's Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials‏
670 ‎‡a  Author's Randomised trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin's disease. Medical Research Council's working party on lymphomas‏
670 ‎‡a  Author's Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda‏
670 ‎‡a  Author's Reaching millennium development goal 4 - the Gambia‏
670 ‎‡a  Author's Reply to Hasford and to Spinola et al‏
670 ‎‡a  Author's Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics‏
670 ‎‡a  Author's Response to Cioffi‏
670 ‎‡a  Author's Response to Dawson et al‏
670 ‎‡a  Author's Risk factors for sporadic Creutzfeldt-Jakob disease.‏
670 ‎‡a  Author's Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial‏
670 ‎‡a  Author's Scale-up of antiretroviral therapy in sub-Saharan Africa: priorities for public health research‏
670 ‎‡a  Author's Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths‏
670 ‎‡a  Author's Sensitivity and negative predictive value for a rapid dengue test‏
670 ‎‡a  Author's Setting research priorities to improve global newborn health and prevent stillbirths by 2025.‏
670 ‎‡a  Author's Sharing clinical trial data.‏
670 ‎‡a  Author's Single-dose liposomal amphotericin B‏
670 ‎‡a  Author's Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial‏
670 ‎‡a  Author's Space-time clustering of Burkitt's lymphoma in the West Nile district of Uganda: 1961-1975‏
670 ‎‡a  Author's Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96‏
670 ‎‡a  Author's Statistical analysis of individually matched case-control studies in epidemiology: factor under study a discrete variable taking multiple values‏
670 ‎‡a  Author's Stratified analysis of case-control studies with the factor under study taking multiple values‏
670 ‎‡a  Author's Survival and the HL-A System in Acute Lymphoblastic Leukaemia‏
670 ‎‡a  Author's The duration of protection of school-aged BCG vaccination in England: a population -based case-control study‏
670 ‎‡a  Author's The effect of intervals between surveys on the estimation of incidence rates of leprosy‏
670 ‎‡a  Author's The entomological inoculation rate and Plasmodium falciparum infection in African children‏
670 ‎‡a  Author's The epidemics of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects‏
670 ‎‡a  Author's The epidemiology of tropical myositis in the Mengo Districts of Uganda‏
670 ‎‡a  Author's The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study‏
670 ‎‡a  Author's The inheritance of translocations in man: data from families ascertained through a balanced heterozygote‏
670 ‎‡a  Author's The prevalence of persistent coughs in a rural community in the Lango district of Uganda‏
670 ‎‡a  Author's The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda‏
670 ‎‡a  Author's The risk of tuberculous infection in Uganda, deprived from the findings of national tuberculin surveys 1958 and 1970.‏
670 ‎‡a  Author's The risk of tuberculous infection in uganda, derived from the findings of national tuberculin surveys in 1958 and 1970☆‏
670 ‎‡a  Author's The Role of Dose Rate, Irradiation Technique, and LET in Determining Radiosensitivities at Low Oxygen Concentrations‏
670 ‎‡a  Author's The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations‏
670 ‎‡a  Author's The serodiagnosis of leprosy‏
670 ‎‡a  Author's The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field‏
670 ‎‡a  Author's Treatment of small-cell carcinoma of bronchus‏
670 ‎‡a  Author's Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study‏
670 ‎‡a  Author's Tuberculosis: old lessons unlearnt?‏
670 ‎‡a  Author's Use of carboxyhaemoglobin levels to predict the development of diseases associated with cigarette smoking‏
670 ‎‡a  Author's Vaccine-attributable severe dengue in the Philippines‏
670 ‎‡a  Author's Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis‏
670 ‎‡a  Author's WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report‏
670 ‎‡a  Author's WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.‏
670 ‎‡a  Author's WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.‏
670 ‎‡a  Author's WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/processed/DNB|1125536438‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/viaf/3768148753691141320000‏
909 ‎‡a  (orcid) 0000000300807560‏ ‎‡9  1‏
919 ‎‡a  doesrespiratorysyncytialviruslowerrespiratoryillnessinearlylifecauserecurrentwheezeofearlychildhoodandasthmacriticalreviewoftheevidenceandguidanceforfuturestudiesfromaworldhealthorganizationsponsoredmeeting‏ ‎‡A  Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting‏ ‎‡9  1‏
919 ‎‡a  casecontrolapproachtoexaminediseasesforevidenceofcontagionincludingdiseaseswithlonglatentperiods‏ ‎‡A  A Case-Control Approach to Examine Diseases for Evidence of Contagion, Including Diseases with Long Latent Periods‏ ‎‡9  2‏
919 ‎‡a  casecontrolstudyofsporadiccreutzfeldtjakobdiseaseintheunitedkingdomanalysisofclustering‏ ‎‡A  A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering.‏ ‎‡9  1‏
919 ‎‡a  clusterrandomisedtrialtocomparehomebasedwithhealthfacilitybasedantiretroviraltreatmentinugandastudydesignandbaselinefindings‏ ‎‡A  A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings‏ ‎‡9  1‏
919 ‎‡a  guidefordiagnosticevaluations‏ ‎‡A  A guide for diagnostic evaluations‏ ‎‡9  1‏
919 ‎‡a  noteonaclosepairstestforspaceclustering‏ ‎‡A  A note on a 'close pairs' test for space clustering‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticstudyofantimalarial35diaryl2aminopyridinederivatives‏ ‎‡A  A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives‏ ‎‡9  1‏
919 ‎‡a  studyofburnsinjuriesinuganda‏ ‎‡A  A study of burns injuries in Uganda‏ ‎‡9  1‏
919 ‎‡a  vaccineagainstmalariaasubstantialstepforward‏ ‎‡A  A vaccine against malaria: a substantial step forward‏ ‎‡9  1‏
919 ‎‡a  analysisoftreatmentinchildhoodleukaemia2timingandthetoxicityofcombined6mercaptopurineandmethotrexatemaintenancetherapy‏ ‎‡A  Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy‏ ‎‡9  1‏
919 ‎‡a  approachestousethewhorespiratorysyncytialvirussurveillanceplatformtoestimatediseaseburden‏ ‎‡A  Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden‏ ‎‡9  1‏
919 ‎‡a  assessmentofthertssas01malariavaccine‏ ‎‡A  Assessment of the RTS,S/AS01 malaria vaccine.‏ ‎‡9  1‏
919 ‎‡a  bovinespongiformencephalopathybseanditsepidemiology‏ ‎‡A  Bovine spongiform encephalopathy (BSE) and its epidemiology‏ ‎‡9  1‏
919 ‎‡a  burkittslymphomainthemengodistrictsofugandaepidemiologicfeaturesandtheirrelationshiptomalaria‏ ‎‡A  Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria‏ ‎‡9  1‏
919 ‎‡a  cancerincidencein5continentscomparisonbetweenregistriesagestandardizedrates‏ ‎‡A  Cancer Incidence in Five Continents. Comparison between registries: age-standardized rates‏ ‎‡9  1‏
919 ‎‡a  casecontrolmethodforseekingevidenceofcontagionincrohnsdisease‏ ‎‡A  Case-control method for seeking evidence of contagion in Crohn's disease‏ ‎‡9  1‏
919 ‎‡a  casecontrolvaccineeffectivenessstudiesdatacollectionanalysisandreportingresults‏ ‎‡A  Case-control vaccine effectiveness studies: Data collection, analysis and reporting results‏ ‎‡9  1‏
919 ‎‡a  casecontrolvaccineeffectivenessstudiespreparationdesignandenrollmentofcasesandcontrols‏ ‎‡A  Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls‏ ‎‡9  1‏
919 ‎‡a  chapter28studiestoassessthelongtermefficacyandeffectivenessofhpvvaccinationindevelopedanddevelopingcountries‏ ‎‡A  Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries‏ ‎‡9  1‏
919 ‎‡a  childhoodpneumoniaandcrowdingbedsharingandnutritionacasecontrolstudyfromthegambia‏ ‎‡A  Childhood pneumonia and crowding, bed-sharing and nutrition: a case-control study from The Gambia‏ ‎‡9  1‏
919 ‎‡a  choicesinvaccinetrialdesigninepidemicsofemerginginfections‏ ‎‡A  Choices in vaccine trial design in epidemics of emerging infections‏ ‎‡9  1‏
919 ‎‡a  clinicaldevelopmentandregulatorypointsforconsiderationfor2generationliveattenuateddenguevaccines‏ ‎‡A  Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.‏ ‎‡9  1‏
919 ‎‡a  clinicaltrialstoestimatetheefficacyofpreventiveinterventionsagainstmalariainpaediatricpopulationsamethodologicalreview‏ ‎‡A  Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review‏ ‎‡9  1‏
919 ‎‡a  comparisonofrapidtestsfordetectionofrifampicinresistantmycobacteriumtuberculosisinkampalauganda‏ ‎‡A  Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda‏ ‎‡9  1‏
919 ‎‡a  congenitalmalformationsadetailedstudyof2500liveborninfants‏ ‎‡A  Congenital malformations; a detailed study of 2500 liveborn infants‏ ‎‡9  1‏
919 ‎‡a  considerationsforusingetecandshigelladiseaseburdenestimatestoguidevaccinedevelopmentstrategy‏ ‎‡A  Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.‏ ‎‡9  1‏
919 ‎‡a  contactsbetweenyoungpatientswithhodgkinsdiseaseacasecontrolstudy‏ ‎‡A  Contacts between young patients with Hodgkin's disease. A case-control study‏ ‎‡9  1‏
919 ‎‡a  controllingdiabetesandhypertensioninsubsaharanafricalessonsfromhivprogrammes‏ ‎‡A  Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes‏ ‎‡9  1‏
919 ‎‡a  creatingaframeworkforconductingrandomizedclinicaltrialsduringdiseaseoutbreaks‏ ‎‡A  Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks‏ ‎‡9  1‏
919 ‎‡a  currentassessmentofcaseclusteringoflymphomasandleukemias‏ ‎‡A  Current assessment of “case clustering” of lymphomas and leukemias‏ ‎‡9  1‏
919 ‎‡a  currentepidemiologicalevidencefortransmissionofhodgkinsdisease‏ ‎‡A  Current epidemiological evidence for transmission of Hodgkin's disease‏ ‎‡9  1‏
919 ‎‡a  deliberationsofthestrategicadvisorygroupofexpertsonimmunizationontheuseofcydtdvdenguevaccine‏ ‎‡A  Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine‏ ‎‡9  1‏
919 ‎‡a  dermatoglyphicsinchildhoodleukaemiaaguidetoprognosisandaetiology‏ ‎‡A  Dermatoglyphics in childhood leukaemia: a guide to prognosis and aetiology?‏ ‎‡9  1‏
919 ‎‡a  dermatoglyphicsinlongtermleukaemicsurvivorsfailuretoconfirmprognosticvalueoffingertippattern‏ ‎‡A  Dermatoglyphics in long-term leukaemic survivors: failure to confirm prognostic value of fingertip pattern‏ ‎‡9  1‏
919 ‎‡a  designandanalysisconsiderationsintheebolatxtrialevaluatingconvalescentplasmainthetreatmentofebolavirusdiseaseinguineaduringthe20142015outbreak‏ ‎‡A  Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak‏ ‎‡9  1‏
919 ‎‡a  designandanalysisofrandomizedclinicaltrialsrequiringprolongedobservationofeachpatient2analysisandexamples‏ ‎‡A  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples‏ ‎‡9  1‏
919 ‎‡a  diseaseclusteringageneralizationofknoxsapproachtothedetectionofspacetimeinteractions‏ ‎‡A  Disease Clustering: A Generalization of Knox's Approach to the Detection of Space-Time Interactions‏ ‎‡9  1‏
919 ‎‡a  doescotrimoxazoletakenbyhivinfectedindividualsreducemortalityamonghivuninfectedfamilymembersdatamaynotsupportconclusion‏ ‎‡A  Does cotrimoxazole taken by HIV-infected individuals reduce mortality among HIV-uninfected family members? Data may not support conclusion‏ ‎‡9  1‏
919 ‎‡a  drugmisusetobaccosmokingalcoholandothersocialdeterminantsoftuberculosisinukbornadultsinenglandacommunitybasedcasecontrolstudy‏ ‎‡A  Drug misuse, tobacco smoking, alcohol and other social determinants of tuberculosis in UK-born adults in England: a community-based case-control study‏ ‎‡9  1‏
919 ‎‡a  durationofeffectivenessofvaccinesagainstsarscov2infectionandcovid19diseaseresultsofasystematicreviewandmetaregression‏ ‎‡A  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression‏ ‎‡9  1‏
919 ‎‡a  effectivenessofthestandardwhorecommendedretreatmentregimencategory2fortuberculosisinkampalaugandaaprospectivecohortstudy‏ ‎‡A  Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study‏ ‎‡9  1‏
919 ‎‡a  efficacyofkilledwholeparasitevaccinesinthepreventionofleishmaniasisametaanalysis‏ ‎‡A  Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis‏ ‎‡9  1‏
919 ‎‡a  efficacyofleprosyvaccine‏ ‎‡A  Efficacy of leprosy vaccine‏ ‎‡9  1‏
919 ‎‡a  embargoonpublicationofscientificpapersbyiranianauthors‏ ‎‡A  Embargo on publication of scientific papers by Iranian authors‏ ‎‡9  1‏
919 ‎‡a  epidemiologicalandpublichealthconsiderationsinthedesignofhivvaccinetrials‏ ‎‡A  Epidemiological and public health considerations in the design of HIV vaccine trials‏ ‎‡9  1‏
919 ‎‡a  epidemiologicalevidenceforcausalrelationshipbetweenepsteinbarrvirusandburkittslymphomafromugandanprospectivestudy‏ ‎‡A  Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study‏ ‎‡9  1‏
919 ‎‡a  epidemiologicalstudiesofthenonspecificeffectsofvaccines1datacollectioninobservationalstudies‏ ‎‡A  Epidemiological studies of the 'non-specific effects' of vaccines: I--data collection in observational studies‏ ‎‡9  1‏
919 ‎‡a  epidemiologyofchildhoodleukaemiaingreaterlondonasearchforevidenceoftransmissionassumingapossiblylonglatentperiod‏ ‎‡A  Epidemiology of childhood leukaemia in greater london: A search for evidence of transmission assuming a possibly long latent period‏ ‎‡9  1‏
919 ‎‡a  epsteinbarrvirusmalariainteractionmodelsforburkittslymphomaimplicationsforpreventivetrials‏ ‎‡A  Epstein-Barr virus-malaria interaction models for Burkitt's lymphoma: implications for preventive trials‏ ‎‡9  1‏
919 ‎‡a  estimatingtheproportionofvaccineinducedhospitalizeddenguecasesamongdengvaxiavaccineesinthephilippines‏ ‎‡A  Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines‏ ‎‡9  1‏
919 ‎‡a  ethicalissuesininterventionstudiesonthepreventionandmanagementofdiabetesandhypertensioninsubsaharanafrica‏ ‎‡A  Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa‏ ‎‡9  1‏
919 ‎‡a  ethicsreviewofcovid19humanchallengestudiesajointhrawhoworkshop‏ ‎‡A  Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop‏ ‎‡9  1‏
919 ‎‡a  evaluationofconvalescentplasmaforebolavirusdiseaseinguinea‏ ‎‡A  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea‏ ‎‡9  1‏
919 ‎‡a  evaluationofdiagnostictestsforinfectiousdiseasesgeneralprinciples‏ ‎‡A  Evaluation of diagnostic tests for infectious diseases: general principles‏ ‎‡9  1‏
919 ‎‡a  evaluationofpostintroductioncovid19vaccineeffectivenesssummaryofinterimguidanceoftheworldhealthorganization‏ ‎‡A  Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization‏ ‎‡9  1‏
919 ‎‡a  familystudiesinacuteleukaemiainchildhoodapossibleassociationwithautoimmunedisease‏ ‎‡A  Family studies in acute leukaemia in childhood: a possible association with autoimmune disease‏ ‎‡9  1‏
919 ‎‡a  1generationleishmaniasisvaccinesareviewoffieldefficacytrials‏ ‎‡A  First generation leishmaniasis vaccines: a review of field efficacy trials‏ ‎‡9  1‏
919 ‎‡a  furtherstudiesofspacetimeclusteringofburkittslymphomainuganda‏ ‎‡A  Further studies of space-time clustering of Burkitt's lymphoma in Uganda‏ ‎‡9  1‏
919 ‎‡a  furtherstudiesonchromosomeaberrationproductionafterwholebodyirradiationinman‏ ‎‡A  Further studies on chromosome aberration production after whole-body irradiation in man‏ ‎‡9  1‏
919 ‎‡a  generalisationsof2testsforthedetectionofhouseholdaggregationofdisease‏ ‎‡A  Generalisations of two tests for the detection of household aggregation of disease‏ ‎‡9  1‏
919 ‎‡a  globaldiarrhoeaassociatedmortalityestimatesandmodelsinchildrenrecommendationsfordatasetandstudyselection‏ ‎‡A  Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection‏ ‎‡9  1‏
919 ‎‡a  guidanceontheevaluationofplasmodiumvivaxvaccinesinpopulationsexposedtonaturalinfection‏ ‎‡A  Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection‏ ‎‡9  1‏
919 ‎‡a  humanchallengestudiestoacceleratecoronavirusvaccinelicensure‏ ‎‡A  Human challenge studies to accelerate coronavirus vaccine licensure‏ ‎‡9  1‏
919 ‎‡a  humanpopulationcytogenetics‏ ‎‡A  Human population cytogenetics‏ ‎‡9  1‏
919 ‎‡a  immunoprophylactictrialwithcombinedmycobacteriumlepraebcgvaccineagainstleprosypreliminaryresults‏ ‎‡A  Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results‏ ‎‡9  1‏
919 ‎‡a  influenceofbirthweightonmortalityfrominfectiousdiseasesacasecontrolstudy‏ ‎‡A  Influence of birth weight on mortality from infectious diseases: a case-control study‏ ‎‡9  1‏
919 ‎‡a  integratinghealthservicesforhivinfectiondiabetesandhypertensioninsubsaharanafricaacohortstudy‏ ‎‡A  Integrating health services for HIV infection, diabetes and hypertension in sub-Saharan Africa: a cohort study‏ ‎‡9  1‏
919 ‎‡a  integratinghivdiabetesandhypertensionservicesinafricastudyprotocolforaclusterrandomisedtrialintanzaniaanduganda‏ ‎‡A  Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda‏ ‎‡9  1‏
919 ‎‡a  kaposissarcomainugandageographicandethnicdistribution‏ ‎‡A  Kaposi's Sarcoma in Uganda: Geographic and Ethnic Distribution‏ ‎‡9  1‏
919 ‎‡a  keycriteriafortheethicalacceptabilityofcovid19humanchallengestudiesreportofawhoworkinggroup‏ ‎‡A  Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group‏ ‎‡9  1‏
919 ‎‡a  leukemiaandothercancersfollowingradiationtreatmentofpelvicdisease‏ ‎‡A  Leukemia and other cancers following radiation treatment of pelvic disease‏ ‎‡9  1‏
919 ‎‡a  leveragingtheglobalinfluenzasurveillanceandresponsesystemforglobalrespiratorysyncytialvirussurveillanceopportunitiesandchallenges‏ ‎‡A  Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges‏ ‎‡9  1‏
919 ‎‡a  liveattenuatedtetravalentdenguevaccinestheneedsandchallengesofpostlicensureevaluationofvaccinesafetyandeffectiveness‏ ‎‡A  Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness‏ ‎‡9  1‏
919 ‎‡a  longtermsafetyassessmentofliveattenuatedtetravalentdenguevaccinesdeliberationsfromawhotechnicalconsultation‏ ‎‡A  Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation‏ ‎‡9  1‏
919 ‎‡a  lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda‏ ‎‡A  Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda‏ ‎‡9  1‏
919 ‎‡a  makingsenseofhealthestimates‏ ‎‡A  Making sense of health estimates‏ ‎‡9  1‏
919 ‎‡a  malariavaccine3or6monthsprotection‏ ‎‡A  Malaria vaccine: 3 or 6 months' protection?‏ ‎‡9  1‏
919 ‎‡a  malvac2008measuresofefficacyofmalariavaccinesinphase2bandphase3trialsscientificregulatoryandpublichealthperspectives‏ ‎‡A  MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives‏ ‎‡9  1‏
919 ‎‡a  measurementofmalariavaccineefficacyinphase3trialsreportofawhoconsultation‏ ‎‡A  Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation‏ ‎‡9  1‏
919 ‎‡a  meetingreportwhoconsultationonacceleratinglassafevervaccinedevelopmentinendemiccountriesdakar1011september‏ ‎‡A  Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries, Dakar, 10-11 September 2019‏ ‎‡9  1‏
919 ‎‡a  mortalityamongpatientswithankylosingspondylitisnotgiven10raytherapy‏ ‎‡A  Mortality among patients with ankylosing spondylitis not given X-ray therapy‏ ‎‡9  1‏
919 ‎‡a  myelosuppressiveeffectofcolaspase50asparaginaseininitialtreatmentofacutelymphoblasticleukaemia‏ ‎‡A  Myelosuppressive Effect of Colaspase (L-Asparaginase) in Initial Treatment of Acute Lymphoblastic Leukaemia‏ ‎‡9  1‏
919 ‎‡a  nonspecificeffectsofbcg‏ ‎‡A  Non-specific effects of BCG?‏ ‎‡9  1‏
919 ‎‡a  nonspecificeffectsofvaccinesanimportantanalyticalinsightandcallforaworkshop‏ ‎‡A  'Non-specific effects of vaccines'--an important analytical insight, and call for a workshop.‏ ‎‡9  1‏
919 ‎‡a  novelvaccinesafetyissuesandareasthatwouldbenefitfromfurtherresearch‏ ‎‡A  Novel vaccine safety issues and areas that would benefit from further research‏ ‎‡9  1‏
919 ‎‡a  observationalstudytoestimatethechangesintheeffectivenessofbacilluscalmetteguerinbcgvaccinationwithtimesincevaccinationforpreventingtuberculosisintheuk‏ ‎‡A  Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.‏ ‎‡9  1‏
919 ‎‡a  persontopersontransmissionofhodgkinsdisease‏ ‎‡A  Person-to-person transmission of hodgkin's disease‏ ‎‡9  1‏
919 ‎‡a  placebouseinvaccinetrialsrecommendationsofawhoexpertpanel‏ ‎‡A  Placebo use in vaccine trials: recommendations of a WHO expert panel‏ ‎‡9  1‏
919 ‎‡a  prospectiveobservationalstudytoevaluatetheclinicalsafetyofthefixeddoseartemisininbasedcombinationeurartesimdihydroartemisininpiperaquineinpublichealthfacilitiesinburkinafasomozambiqueghanaandtanzania‏ ‎‡A  Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania‏ ‎‡9  1‏
919 ‎‡a  protectionbybcgvaccineagainsttuberculosisasystematicreviewofrandomizedcontrolledtrials‏ ‎‡A  Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials‏ ‎‡9  1‏
919 ‎‡a  randomisedtrialof2drugand4drugmaintenancechemotherapyinadvancedorrecurrenthodgkinsdiseasemedicalresearchcouncilsworkingpartyonlymphomas‏ ‎‡A  Randomised trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin's disease. Medical Research Council's working party on lymphomas‏ ‎‡9  1‏
919 ‎‡a  rateandamplificationofdrugresistanceamongpreviouslytreatedpatientswithtuberculosisinkampalauganda‏ ‎‡A  Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda‏ ‎‡9  1‏
919 ‎‡a  reachingmillenniumdevelopmentgoal4thegambia‏ ‎‡A  Reaching millennium development goal 4 - the Gambia‏ ‎‡9  1‏
919 ‎‡a  replytohasfordandtospinolaetal‏ ‎‡A  Reply to Hasford and to Spinola et al‏ ‎‡9  1‏
919 ‎‡a  respiratorysyncytialvirusvaccineresearchanddevelopmentworldhealthorganizationtechnologicalroadmapandpreferredproductcharacteristics‏ ‎‡A  Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics‏ ‎‡9  1‏
919 ‎‡a  responsetocioffi‏ ‎‡A  Response to Cioffi‏ ‎‡9  1‏
919 ‎‡a  responsetodawsonetal‏ ‎‡A  Response to Dawson et al‏ ‎‡9  1‏
919 ‎‡a  riskfactorsforsporadiccreutzfeldtjakobdisease‏ ‎‡A  Risk factors for sporadic Creutzfeldt-Jakob disease.‏ ‎‡9  1‏
919 ‎‡a  safetyandefficacyofsingledoseversusmultipledosesofambisomefortreatmentofvisceralleishmaniasisineasternafricaarandomisedtrial‏ ‎‡A  Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial‏ ‎‡9  1‏
919 ‎‡a  scaleupofantiretroviraltherapyinsubsaharanafricaprioritiesforpublichealthresearch‏ ‎‡A  Scale-up of antiretroviral therapy in sub-Saharan Africa: priorities for public health research‏ ‎‡9  1‏
919 ‎‡a  selectionandquantificationofinfectionendpointsfortrialsofvaccinesagainstintestinalhelminths‏ ‎‡A  Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths‏ ‎‡9  1‏
919 ‎‡a  sensitivityandnegativepredictivevalueforarapiddenguetest‏ ‎‡A  Sensitivity and negative predictive value for a rapid dengue test‏ ‎‡9  1‏
919 ‎‡a  settingresearchprioritiestoimproveglobalnewbornhealthandpreventstillbirthsby‏ ‎‡A  Setting research priorities to improve global newborn health and prevent stillbirths by 2025.‏ ‎‡9  1‏
919 ‎‡a  sharingclinicaltrialdata‏ ‎‡A  Sharing clinical trial data.‏ ‎‡9  1‏
919 ‎‡a  singledoseliposomalamphotericinb‏ ‎‡A  Single-dose liposomal amphotericin B‏ ‎‡9  1‏
919 ‎‡a  singledoseliposomalamphotericinbambisomeforthetreatmentofvisceralleishmaniasisineastafricastudyprotocolforarandomizedcontrolledtrial‏ ‎‡A  Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial‏ ‎‡9  1‏
919 ‎‡a  spacetimeclusteringofburkittslymphomainthewestniledistrictofuganda1961‏ ‎‡A  Space-time clustering of Burkitt's lymphoma in the West Nile district of Uganda: 1961-1975‏ ‎‡9  1‏
919 ‎‡a  sporadiccreutzfeldtjakobdiseaseintheunitedkingdomanalysisofepidemiologicalsurveillancedatafor197096‏ ‎‡A  Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96‏ ‎‡9  1‏
919 ‎‡a  statisticalanalysisofindividuallymatchedcasecontrolstudiesinepidemiologyfactorunderstudyadiscretevariabletakingmultiplevalues‏ ‎‡A  Statistical analysis of individually matched case-control studies in epidemiology: factor under study a discrete variable taking multiple values‏ ‎‡9  1‏
919 ‎‡a  stratifiedanalysisofcasecontrolstudieswiththefactorunderstudytakingmultiplevalues‏ ‎‡A  Stratified analysis of case-control studies with the factor under study taking multiple values‏ ‎‡9  1‏
919 ‎‡a  survivalandthehlasysteminacutelymphoblasticleukaemia‏ ‎‡A  Survival and the HL-A System in Acute Lymphoblastic Leukaemia‏ ‎‡9  1‏
919 ‎‡a  durationofprotectionofschoolagedbcgvaccinationinenglandapopulationbasedcasecontrolstudy‏ ‎‡A  The duration of protection of school-aged BCG vaccination in England: a population -based case-control study‏ ‎‡9  1‏
919 ‎‡a  effectofintervalsbetweensurveysontheestimationofincidenceratesofleprosy‏ ‎‡A  The effect of intervals between surveys on the estimation of incidence rates of leprosy‏ ‎‡9  1‏
919 ‎‡a  entomologicalinoculationrateandplasmodiumfalciparuminfectioninafricanchildren‏ ‎‡A  The entomological inoculation rate and Plasmodium falciparum infection in African children‏ ‎‡9  1‏
919 ‎‡a  epidemicsofbovinespongiformencephalopathyandvariantcreutzfeldtjakobdiseasecurrentstatusandfutureprospects‏ ‎‡A  The epidemics of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects‏ ‎‡9  1‏
919 ‎‡a  epidemiologyoftropicalmyositisinthemengodistrictsofuganda‏ ‎‡A  The epidemiology of tropical myositis in the Mengo Districts of Uganda‏ ‎‡9  1‏
919 ‎‡a  impactofchildhoodvaccinesonbacterialcarriageinthenasopharynxalongitudinalstudy‏ ‎‡A  The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study‏ ‎‡9  1‏
919 ‎‡a  inheritanceoftranslocationsinmandatafromfamiliesascertainedthroughabalancedheterozygote‏ ‎‡A  The inheritance of translocations in man: data from families ascertained through a balanced heterozygote‏ ‎‡9  1‏
919 ‎‡a  prevalenceofpersistentcoughsinaruralcommunityinthelangodistrictofuganda‏ ‎‡A  The prevalence of persistent coughs in a rural community in the Lango district of Uganda‏ ‎‡9  1‏
919 ‎‡a  protectiveeffectofbcgagainstmycobacteriumulceransdiseaseacontrolledtrialinanendemicareaofuganda‏ ‎‡A  The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda‏ ‎‡9  1‏
919 ‎‡a  riskoftuberculousinfectioninugandadeprivedfromthefindingsofnationaltuberculinsurveys1958and‏ ‎‡A  The risk of tuberculous infection in Uganda, deprived from the findings of national tuberculin surveys 1958 and 1970.‏ ‎‡9  1‏
919 ‎‡a  riskoftuberculousinfectioninugandaderivedfromthefindingsofnationaltuberculinsurveysin1958and1970‏ ‎‡A  The risk of tuberculous infection in uganda, derived from the findings of national tuberculin surveys in 1958 and 1970☆‏ ‎‡9  1‏
919 ‎‡a  roleofdoserateirradiationtechniqueandletindeterminingradiosensitivitiesatlowoxygenconcentrations‏ ‎‡A  The Role of Dose Rate, Irradiation Technique, and LET in Determining Radiosensitivities at Low Oxygen Concentrations‏ ‎‡9  1‏
919 ‎‡a  roleofimmunecorrelatesofprotectiononthepathwaytolicensurepolicydecisionanduseofgroupbstreptococcusvaccinesformaternalimmunizationconsiderationsfromworldhealthorganizationconsultations‏ ‎‡A  The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations‏ ‎‡9  1‏
919 ‎‡a  serodiagnosisofleprosy‏ ‎‡A  The serodiagnosis of leprosy‏ ‎‡9  1‏
919 ‎‡a  useofebolaconvalescentplasmatotreatebolavirusdiseaseinresourceconstrainedsettingsaperspectivefromthefield‏ ‎‡A  The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field‏ ‎‡9  1‏
919 ‎‡a  treatmentofsmallcellcarcinomaofbronchus‏ ‎‡A  Treatment of small-cell carcinoma of bronchus‏ ‎‡9  1‏
919 ‎‡a  treatmentoutcomesofnewtuberculosispatientshospitalizedinkampalaugandaaprospectivecohortstudy‏ ‎‡A  Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study‏ ‎‡9  1‏
919 ‎‡a  tuberculosisoldlessonsunlearnt‏ ‎‡A  Tuberculosis: old lessons unlearnt?‏ ‎‡9  1‏
919 ‎‡a  useofcarboxyhaemoglobinlevelstopredictthedevelopmentofdiseasesassociatedwithcigarettesmoking‏ ‎‡A  Use of carboxyhaemoglobin levels to predict the development of diseases associated with cigarette smoking‏ ‎‡9  1‏
919 ‎‡a  vaccineattributableseveredengueinthephilippines‏ ‎‡A  Vaccine-attributable severe dengue in the Philippines‏ ‎‡9  1‏
919 ‎‡a  variabilityofinfectiousaerosolsproducedduringcoughingbypatientswithpulmonarytuberculosis‏ ‎‡A  Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis‏ ‎‡9  1‏
919 ‎‡a  whoconsultationonetecandshigellaburdenofdiseasegeneva67april2017meetingreport‏ ‎‡A  WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report‏ ‎‡9  1‏
919 ‎‡a  whoconsultationongroupbstreptococcusvaccinedevelopmentreportfromameetingheldon2728april‏ ‎‡A  WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.‏ ‎‡9  1‏
919 ‎‡a  whoconsultationonrespiratorysyncytialvirusvaccinedevelopmentreportfromaworldhealthorganizationmeetingheldon2324march‏ ‎‡A  WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.‏ ‎‡9  1‏
919 ‎‡a  whopreferredproductcharacteristicsformonoclonalantibodiesforpassiveimmunizationagainstrespiratorysyncytialvirusrsvdiseaseininfantskeyconsiderationsforglobaluse‏ ‎‡A  WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use‏ ‎‡9  1‏
943 ‎‡a  201x‏ ‎‡A  2019‏ ‎‡9  3‏
943 ‎‡a  202x‏ ‎‡A  2025‏ ‎‡9  1‏
943 ‎‡a  197x‏ ‎‡A  1975‏ ‎‡9  2‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  CAOONL|ncf10522087‏
996 ‎‡2  SUDOC|052578267‏
996 ‎‡2  DBC|87097947348943‏
996 ‎‡2  NUKAT|n 2012070017‏
996 ‎‡2  ISNI|0000000047307086‏
996 ‎‡2  LC|n 84141874‏
996 ‎‡2  NDL|031644399‏
996 ‎‡2  LC|n 92004819‏
996 ‎‡2  J9U|987007407837505171‏
996 ‎‡2  BIBSYS|90631541‏
996 ‎‡2  J9U|987007460683505171‏
996 ‎‡2  ISNI|0000000075626068‏
996 ‎‡2  RERO|A012887451‏
996 ‎‡2  LC|no2008038686‏
996 ‎‡2  DNB|170188426‏
996 ‎‡2  LC|n 85312547‏
996 ‎‡2  BNF|12382123‏
996 ‎‡2  LC|n 99264788‏
996 ‎‡2  SUDOC|033007322‏
996 ‎‡2  LC|nr 95013248‏
996 ‎‡2  BIBSYS|90085818‏
996 ‎‡2  DNB|1210720329‏
996 ‎‡2  NTA|072724900‏
996 ‎‡2  CAOONL|ncf11196146‏
996 ‎‡2  RERO|A017315084‏
996 ‎‡2  BNF|12166904‏
996 ‎‡2  LC|no 96025173‏
996 ‎‡2  LNB|LNC10-000117600‏
996 ‎‡2  SUDOC|153542772‏
996 ‎‡2  ISNI|0000000066835669‏
996 ‎‡2  BNC|981058517419506706‏
996 ‎‡2  LC|n 95038403‏
996 ‎‡2  SUDOC|164464956‏
996 ‎‡2  LNB|LNC10-000024951‏
996 ‎‡2  NTA|072346787‏
996 ‎‡2  SUDOC|031970850‏
996 ‎‡2  RERO|A003195632‏
996 ‎‡2  LC|nb2020009489‏
996 ‎‡2  NTA|068309317‏
996 ‎‡2  LC|n 2007026086‏
996 ‎‡2  ISNI|0000000452745274‏
996 ‎‡2  DNB|120768275‏
996 ‎‡2  ISNI|0000000021626046‏
996 ‎‡2  NII|DA01718444‏
996 ‎‡2  NTA|096950919‏
996 ‎‡2  NLA|000035507567‏
996 ‎‡2  LC|n 90684808‏
996 ‎‡2  W2Z|1512647516188‏
996 ‎‡2  LC|n 79062101‏
996 ‎‡2  BIBSYS|90172505‏
996 ‎‡2  ISNI|0000000386122772‏
996 ‎‡2  CAOONL|ncf10428875‏
996 ‎‡2  LC|n 77002749‏
996 ‎‡2  LC|nb2008016315‏
996 ‎‡2  NII|DA02700670‏
996 ‎‡2  LIH|LNB:B53_i_;=BJ‏
996 ‎‡2  NUKAT|n 2022160021‏
996 ‎‡2  LC|n 80098842‏
996 ‎‡2  LC|no2020030184‏
996 ‎‡2  J9U|987008523966605171‏
996 ‎‡2  NTA|100129498‏
996 ‎‡2  ISNI|0000000114433753‏
996 ‎‡2  ISNI|0000000027296236‏
996 ‎‡2  NII|DA04559449‏
996 ‎‡2  ISNI|0000000025314760‏
996 ‎‡2  ISNI|0000000043324161‏
996 ‎‡2  NUKAT|n 2004083044‏
996 ‎‡2  NUKAT|n 2003063682‏
996 ‎‡2  ISNI|0000000030269132‏
996 ‎‡2  PLWABN|9810598496805606‏
996 ‎‡2  NII|DA06646941‏
996 ‎‡2  ISNI|0000000124342687‏
996 ‎‡2  ISNI|0000000371570329‏
996 ‎‡2  NTA|07286687X‏
996 ‎‡2  DNB|124142931‏
996 ‎‡2  ISNI|0000000034942726‏
996 ‎‡2  LC|no2018074685‏
996 ‎‡2  ISNI|0000000052935343‏
996 ‎‡2  LC|no2017039093‏
996 ‎‡2  J9U|987007463283305171‏
996 ‎‡2  NUKAT|n 99028131‏
996 ‎‡2  NDL|001146466‏
996 ‎‡2  RERO|A003839854‏
996 ‎‡2  BNC|981058525810406706‏
996 ‎‡2  RERO|A003839859‏
996 ‎‡2  RERO|A003839858‏
996 ‎‡2  NTA|069332673‏
996 ‎‡2  LC|n 85233795‏
996 ‎‡2  NLA|000035428222‏
996 ‎‡2  ISNI|0000000445170177‏
996 ‎‡2  LC|no 00046772‏
996 ‎‡2  BAV|495_261929‏
996 ‎‡2  SUDOC|115489347‏
996 ‎‡2  LC|n 83171999‏
996 ‎‡2  ISNI|0000000021761846‏
996 ‎‡2  NUKAT|n 2010081612‏
996 ‎‡2  ISNI|0000000083652282‏
996 ‎‡2  NUKAT|n 2006118990‏
996 ‎‡2  ISNI|0000000026521454‏
996 ‎‡2  ISNI|0000000387650163‏
996 ‎‡2  NLA|000035497117‏
996 ‎‡2  LC|no2003106576‏
996 ‎‡2  BLBNB|000357510‏
996 ‎‡2  NTA|304364053‏
996 ‎‡2  RERO|A025608616‏
996 ‎‡2  CAOONL|ncf10626865‏
996 ‎‡2  NUKAT|n 2003036348‏
996 ‎‡2  BIBSYS|1642068464364‏
996 ‎‡2  ISNI|000000040194568X‏
996 ‎‡2  NTA|187353255‏
996 ‎‡2  LC|no2022137705‏
996 ‎‡2  NII|DA05250490‏
996 ‎‡2  SIMACOB|44256867‏
996 ‎‡2  LC|n 81135333‏
996 ‎‡2  J9U|987007264854705171‏
996 ‎‡2  SUDOC|24241267X‏
996 ‎‡2  DBC|87097939535246‏
996 ‎‡2  BIBSYS|90544024‏
996 ‎‡2  BIBSYS|90544025‏
996 ‎‡2  ISNI|0000000086459840‏
996 ‎‡2  ISNI|0000000029343745‏
996 ‎‡2  CAOONL|ncf10203326‏
996 ‎‡2  DNB|1145431046‏
996 ‎‡2  ISNI|0000000030032821‏
996 ‎‡2  NUKAT|n 2011102786‏
996 ‎‡2  J9U|987007437418705171‏
996 ‎‡2  LC|n 88661712‏
996 ‎‡2  ISNI|0000000074017279‏
996 ‎‡2  NSK|000725147‏
996 ‎‡2  NSK|000036179‏
996 ‎‡2  LC|nr 93018914‏
996 ‎‡2  ISNI|0000000120063445‏
996 ‎‡2  LC|n 80033076‏
996 ‎‡2  DNB|173709117‏
996 ‎‡2  SUDOC|198737912‏
996 ‎‡2  PLWABN|9813203820905606‏
996 ‎‡2  LC|n 92020381‏
996 ‎‡2  SUDOC|146674316‏
996 ‎‡2  ISNI|0000000074358946‏
996 ‎‡2  NKC|vse2008462666‏
996 ‎‡2  NII|DA08305114‏
996 ‎‡2  PLWABN|9810567355705606‏
996 ‎‡2  ISNI|0000000114909117‏
996 ‎‡2  NUKAT|n 2009170019‏
996 ‎‡2  BNC|981058524042806706‏
996 ‎‡2  CAOONL|ncf11164262‏
996 ‎‡2  BIBSYS|2064279‏
996 ‎‡2  LC|no2024006273‏
996 ‎‡2  DNB|1023822105‏
996 ‎‡2  J9U|987007435054105171‏
996 ‎‡2  ISNI|0000000498223228‏
996 ‎‡2  BNF|12308919‏
996 ‎‡2  LC|n 86058278‏
996 ‎‡2  RERO|A017315056‏
996 ‎‡2  RERO|A017315059‏
996 ‎‡2  SUDOC|261269658‏
996 ‎‡2  BIBSYS|90184238‏
996 ‎‡2  BNF|12565820‏
996 ‎‡2  LC|n 93012255‏
996 ‎‡2  LC|n 86102736‏
996 ‎‡2  BNC|981058517419606706‏
996 ‎‡2  BNF|13752683‏
996 ‎‡2  BLBNB|000506862‏
996 ‎‡2  LC|nb2018013177‏
996 ‎‡2  NTA|070946760‏
996 ‎‡2  BLBNB|000506866‏
996 ‎‡2  DNB|128300027X‏
996 ‎‡2  VLACC|000002221‏
996 ‎‡2  VLACC|000002222‏
996 ‎‡2  LC|no2015077900‏
996 ‎‡2  NUKAT|n 2019143472‏
996 ‎‡2  NII|DA02166092‏
996 ‎‡2  NKC|mub20211108669‏
996 ‎‡2  LC|no2022138804‏
996 ‎‡2  LC|no2023022359‏
996 ‎‡2  NUKAT|n 2004045735‏
996 ‎‡2  NTA|307574733‏
996 ‎‡2  SUDOC|079880320‏
996 ‎‡2  LC|nb2013005009‏
996 ‎‡2  NTA|158661834‏
996 ‎‡2  W2Z|99007586‏
996 ‎‡2  LC|nb2016008066‏
996 ‎‡2  LC|n 2009059032‏
996 ‎‡2  DNB|188484493‏
996 ‎‡2  NDL|00456986‏
996 ‎‡2  LC|no2006111783‏
996 ‎‡2  RERO|A003839846‏
996 ‎‡2  LC|n 82003889‏
996 ‎‡2  CAOONL|ncf10983787‏
996 ‎‡2  J9U|987007431414105171‏
996 ‎‡2  SUDOC|164491953‏
996 ‎‡2  LC|nb2023015419‏
996 ‎‡2  SUDOC|27949176X‏
996 ‎‡2  CAOONL|ncf10933970‏
996 ‎‡2  BNF|12811103‏
996 ‎‡2  LC|n 92022345‏
996 ‎‡2  J9U|987007390732205171‏
996 ‎‡2  LC|n 81149741‏
996 ‎‡2  ISNI|0000000108155574‏
996 ‎‡2  BIBSYS|97024875‏
996 ‎‡2  N6I|vtls000341647‏
996 ‎‡2  NTA|072676248‏
996 ‎‡2  CAOONL|ncf10222566‏
996 ‎‡2  LNB|LNC10-000030118‏
996 ‎‡2  ISNI|0000000049699896‏
996 ‎‡2  LC|n 85245494‏
996 ‎‡2  LNB|LNC10-000137619‏
996 ‎‡2  LC|no2015131457‏
996 ‎‡2  LC|no2020141124‏
996 ‎‡2  J9U|987007269820205171‏
996 ‎‡2  NTA|074511777‏
996 ‎‡2  NTA|073404934‏
996 ‎‡2  BNC|981058516230506706‏
996 ‎‡2  RERO|A027732390‏
996 ‎‡2  J9U|987007331430905171‏
996 ‎‡2  LC|no2017106902‏
996 ‎‡2  LC|nb2003058489‏
996 ‎‡2  LC|n 2007021964‏
996 ‎‡2  BIBSYS|90731571‏
996 ‎‡2  NII|DA04149844‏
996 ‎‡2  DNB|1223207765‏
996 ‎‡2  BIBSYS|13031397‏
996 ‎‡2  LC|no2007086364‏
996 ‎‡2  LC|nb2001072957‏
996 ‎‡2  SELIBR|293837‏
996 ‎‡2  LC|no2009059271‏
996 ‎‡2  ISNI|0000000043057534‏
996 ‎‡2  ISNI|0000000117348351‏
996 ‎‡2  LIH|LNB:B3_n_7;=BQ‏
996 ‎‡2  PLWABN|9810612156705606‏
996 ‎‡2  ISNI|0000000380259444‏
996 ‎‡2  ISNI|000000012006451X‏
996 ‎‡2  RERO|A003839855‏
996 ‎‡2  DNB|129472182‏
996 ‎‡2  NUKAT|n 2006118502‏
996 ‎‡2  LC|n 81110566‏
996 ‎‡2  BIBSYS|98024764‏
996 ‎‡2  LC|n 88616293‏
996 ‎‡2  SUDOC|086118773‏
996 ‎‡2  DNB|123144965‏
996 ‎‡2  SUDOC|201767619‏
996 ‎‡2  NKC|ctu2015862373‏
996 ‎‡2  SUDOC|266500528‏
996 ‎‡2  LC|n 50013309‏
996 ‎‡2  SUDOC|110418387‏
996 ‎‡2  LC|n 2001010779‏
996 ‎‡2  NII|DA0073414X‏
996 ‎‡2  ISNI|0000000108766308‏
996 ‎‡2  DNB|1050115031‏
996 ‎‡2  LC|n 95063906‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Smith, Peter G.‏ ‎‡2  DNB|1125536438‏ ‎‡3  suggested‏ ‎‡3  standard number‏